Retargeting clinicians: four limits for device companies
Meta can classify a device company’s whole website as health-related and strip its conversion events, and the company cannot change that classification. Which pages carry ad tags has to be decided before the first tag goes on.
This page is general information, checked against the sources named in it on 29 October 2026. The company’s regulatory and privacy counsel decide for its device and its markets.
The four limits are drawn from the ad platforms’ terms and the device advertising rules quoted below.
- Ad tags go on pages written for professionals, and fire only after consent. Pages for hospitals, clinics, purchasing teams and clinicians may carry ad tags once the visitor accepts, through one banner for every visitor with a way to withdraw. Patient pages, scientific exchange requests and any form that asks about a person’s own health carry none.
- Audiences come from job, employer and site visit. Google, Meta and LinkedIn all bar targeting on a health condition, and every uploaded list comes from the company’s own relationships, with the consent the law asks for.
- Ads say only what each market’s regulatory stage allows. Before authorization, the paid work in a market speaks about the company, its people, the clinical problem and the published science.
- Exposure in uncleared markets is limited through campaign geography, market-status lines and professional-only areas.
Ad tags: professional pages, after consent
| Page on the company’s site | Ad tags | Feeds audiences |
|---|---|---|
| Pages written for hospitals, clinics, purchasing teams and clinicians: the product overview for professionals, evidence pages, the value analysis pack, conference follow-up | After consent, through a setting on each page | Yes, by job, employer and site visit |
| The professional section, where a market asks for a verified area | As above, behind a professional check for visitors from that market | Yes |
| Patient and public pages about a condition, a symptom, a procedure or a treatment | None | No |
| Any form that asks about a person’s own health, a trial, an appointment or a referral, and its thank-you page | None | No |
| The scientific exchange request, routed to the clinical team | None | No |
| Investor, careers and company news pages | After consent | Investor and talent audiences |
LinkedIn says its Insight Tag “should not be installed on web pages that collect or contain Sensitive Data”, and it names “business-to-business pages directed only to organizations and financial or healthcare professionals” as a place the tag may go. Meta’s Business Tools Terms bar sending data that “includes or is based on, directly or otherwise, health information”, so on a professional page I check every web address parameter and event name a Meta tag would send before it runs. The European Union’s top court held in 2023 that visits to websites “may, in certain cases, reveal” sensitive information such as health.
Google’s own clause is narrower: “You may not upload conversion information related to sensitive categories”. Keeping its tag off patient pages as well is my own caution. The conversion feeds sent from the company’s server follow the same split, with nothing that names a condition and nothing from a patient page.
Sources, checked 29 October 2026: LinkedIn, Insight Tag and sensitive data; Meta Business Tools Terms; Court of Justice, case C-252/21, paragraph 72; Google, sensitive conversions.
Ad content by regulatory stage
The table is the lower-risk version. Each piece is still judged on its purpose and context: Health Canada weighs the sponsor, the content, the context, the audience and the frequency, so a page that keeps repeating device messages to buyers can count as advertising without making a single claim.
| Stage in a market | May carry | May never carry |
|---|---|---|
| Investigational device, United States | The company and its team; the clinical problem, with sources; published data labelled investigational; scientific exchange requests routed to clinical staff; conference and publication news; a news list | Promotion or test marketing; any statement that the device is safe or effective; price; orders |
| Awaiting 510(k) clearance, United States | As above, and the device may be shown and advertised | Orders, or readiness to take them |
| Before a licence, Canada, Class II to IV | As the investigational row | Advertising the device for sale |
| Before Conformité Européenne (CE) marking, European Union | As the investigational row; at trade fairs, the device with a visible demonstration-only sign | Device promotion of any kind. The regulation bars uses outside the assessed purpose and national laws add more, so I treat the whole union this way as my own caution |
| Before approval in Japan, India or Saudi Arabia | As the investigational row; in Japan, without the device’s name or performance | Any device advertising; in Saudi Arabia, any device ad without the regulator’s approval first |
| Cleared or licensed in that market | Claims inside the cleared indications for use, each traced to its evidence, one claim set per market | Claims outside the cleared indications; public advertising where national law limits it, as Germany and Singapore do |
| Trade shows, before clearance in the host market | The device, with a visible sign that it is for demonstration only and not for sale | Orders and price lists |
The clauses behind the table, quoted:
- United States, investigational device. The Food and Drug Administration (FDA) rule is Title 21 of the Code of Federal Regulations (CFR), section 812.7: nobody acting for a sponsor shall “(a) Promote or test market an investigational device, until after FDA has approved the device for commercial distribution”, or “(d) Represent that an investigational device is safe or effective for the purposes for which it is being investigated.”
- United States, 510(k) pending. FDA’s compliance policy: “a firm may advertise or display a device that is the subject of a pending 510(k)”, while “a firm may not take orders, or be prepared to take orders, that might result in contracts of sale for the device unless limited to research or investigational use”.
- Canada. Section 27 of the Medical Devices Regulations: nobody may advertise a Class II, III or IV device for the purpose of sale until the manufacturer holds a licence, or an authorization under section 68.12, with one narrow exception for a catalogue that carries a clear warning.
- European Union. The Medical Device Regulation, Article 7, bars advertising that suggests “uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out”. Article 21(3) lets a device that is not yet compliant be shown at trade fairs if “a visible sign clearly indicates that such devices are intended for presentation or demonstration purposes only”. The United Kingdom has the same trade-fair rule.
- Japan. Article 68 of the Pharmaceuticals and Medical Devices Act: “No person may advertise the name, manufacturing process, efficacy, effects or performance of” a device that has not yet been approved or certified there.
- India. The Uniform Code for Medical Device Marketing Practices: “A Medical Device must not be promoted prior to receipt of the product approval (wherever applicable)”.
- Saudi Arabia. The Saudi Food and Drug Authority’s approval “shall be obtained prior to publishing advertising material for medical devices, whether it is aimed to laypersons or healthcare practitioners”.
Sources, checked 29 October 2026: 21 CFR 812.7; FDA, Compliance Policy Guide Sec. 300.600; Medical Devices Regulations, section 27; Health Canada, Distinction Between Advertising and Other Activities; Medical Device Regulation 2017/745; United Kingdom Medical Devices Regulations 2002, regulation 12; Japan, Article 68, official translation; India, device marketing code, amended 30 April 2026; Saudi Food and Drug Authority, requirements document 8, version 4.
Exposure limits across jurisdictions
- One consent banner for every visitor. Ad tags load only after Accept, and a withdrawal stops them. In the European Union, storing or reading information on a visitor’s device “is only allowed on condition that the subscriber or user concerned has given his or her consent”, and the United Kingdom’s regulator says “The use of storage and access technologies for online advertising purposes requires consent”. The California Consumer Privacy Act (CCPA) gives people an opt-out of “selling or sharing” their information with businesses above its thresholds, which must honour Global Privacy Control signals, and it covers business contacts too. Everywhere else one banner is my choice: it is simpler than rules by geography, and on a site for professionals it costs little reach.
- One market-status line on every device page, near the top: where the device is cleared, licensed or exempt, with the number, and that it is not for sale elsewhere. The line lowers the risk; it cannot make a page lawful in a market that restricts it.
- A verified area for professionals where a market asks for one. Singapore allows ads for “professional use only” devices only to practitioners, and Saudi Arabia says “It is not permitted to display information intended for healthcare professionals on websites designated for laypersons”. For visitors from those markets, the device pages for professionals sit behind a check.
- Campaigns aim only at cleared markets, and only at professional audiences where national law limits public device advertising, as Germany and Singapore do. Location targeting is approximate, so geography limits the exposure in an uncleared market without removing it, and the regulatory reviewers confirm each campaign’s markets before it runs.
- No campaigns into Japan, China, Saudi Arabia, the United Arab Emirates or South Korea until the local distributor or regulatory agent confirms the approval route for the ad itself. Australia and Brazil follow the same route until their primary texts are checked.
Sources, checked 29 October 2026: ePrivacy Directive, Article 5(3); Information Commissioner’s Office, storage and access technologies; California Privacy Protection Agency; Singapore Health Sciences Authority; Germany, Heilmittelwerbegesetz.
Platforms: LinkedIn, Google, Meta
LinkedIn is the main paid channel for hospital and clinician audiences. Its rule for devices is legality: “Ads may only promote medical devices and medical treatments where it is legal.” It allows targeting by job title, function, skills and employer, and it bars targeting on “data concerning health”. A campaign needs at least 300 matched members, and a job or specialty filter narrows a list of hospitals fast, so I estimate the matched audience in LinkedIn’s Campaign Manager before any campaign is planned. Thought Leader Ads, which sponsor a founder’s or a clinician’s own post with their permission, face the same minimum.
Google is planned for search and context first. For a device that treats or manages a chronic condition, Google’s Health category applies, and there “You can’t use advertiser-curated audiences”, which takes out remarketing lists for consumer-facing campaigns. Since 29 May 2025 the category excludes “content directed at healthcare professionals in their professional capacity”, so a campaign written for clinicians may qualify for remarketing after Google’s review. Customer Match targeting needs “90 days of Google Ads history and more than USD $50,000 total lifetime spend” (United States dollars), and only customer information “collected in the first-party context”.
Meta is planned for awareness. Meta classifies the website itself, and a site “associated with medical conditions or specific health statuses” or with “health-related products and services” can lose the parameters in its web addresses, its mid and lower funnel events, or all of its events; “you will not be able to modify a Meta-assigned categorization”. Meta also removed its health-related detailed targeting options on 19 January 2022. So Meta is used for reach and video views, with its tag limited to checked professional pages, or left out.
Sources, checked 29 October 2026: LinkedIn Advertising Policies; LinkedIn, audience size; LinkedIn, Thought Leader Ads; Google, Health category; Google, policy update of 29 May 2025; Google, Customer Match; Meta, data source categories; Meta, targeting changes of 2022.
Geofencing, clinician voices and email
- No geofencing around hospitals or clinics. Washington’s My Health My Data Act says “It is unlawful for any person to implement a geofence around an entity that provides in-person health care services”, within 2,000 feet. Everywhere else it is my own caution, because a geofence cannot tell a purchasing manager from a patient.
- Paid clinician voices are disclosed. A clinician who hosts a sponsored podcast or lends a post to a Thought Leader Ad discloses the connection; the Federal Trade Commission’s Endorsement Guides say it “must be disclosed clearly and conspicuously”. My default is a written agreement at fair market value, and the payment is reported in the Open Payments program where its rules apply. Singapore says device ads “should not carry testimonials or recommendations by healthcare professionals”, and India’s code says “The names or photographs of healthcare professionals must not be used in the promotional material.”
- Email to the United States honours each opt-out within 10 business days and carries a valid postal address in every message.
Sources, checked 29 October 2026: Revised Code of Washington, chapter 19.373; 16 CFR 255.5; 42 CFR 403.904; Federal Trade Commission, commercial email compliance guide.
What changed, as of 29 October
Google’s exclusion for content written for clinicians arrived on 29 May 2025. LinkedIn updated its Ads Agreement on 3 November 2025 and its advertising policies on 18 November 2025, and Meta’s Business Tools Terms took effect on 3 November 2025. In the United Kingdom, the rule on storing and reading information on a visitor’s device was replaced on 5 February 2026, and the regulator’s guidance followed on 29 April 2026. India amended its device marketing code on 30 April 2026, and Saudi Arabia published version 4.0 of its device advertising requirements on 20 July 2026. I check every source on this page again each quarter.
The tag map, the audiences and the approval procedure are built with the company’s regulatory and privacy counsel, who decide for its device and its markets. I build the go-to-market work inside their answers. The eight workstreams and the clearance week checklist show where the tags, audiences and paid phases fit.
This site follows the same rules for its own audience: one consent banner, LinkedIn’s tag loads only after a visitor accepts, and no page here asks about anyone’s health.
A device company can retarget clinicians when the ad tags sit only on professional pages, fire after consent, target by job and employer, and advertise the device only where it is cleared.
Tell me your origin story
We book 1 to 2 hours. It is recorded, with a mutual non-disclosure agreement in place at booking, so you can talk openly about why you’re building this, the customers, pricing and pipeline decisions that are keeping you up at night. For a device company the agenda adds the four questions after clearance, and the playbook carries one page on what is known, what is unknown and who answers each.
From that session, you’ll get a written playbook, broken into steps your team can actually take.
It costs $25. Basically enough to cover the tokens to analyze our call and build out your report. I’m definitely not making money off this. But I am committed to showing up and using our time well. If the session isn’t worth your hour, I’ll double your refund: $50, as an apology for wasting your time.